

Down syndrome - Pipeline Insight, 2021

<https://marketpublishers.com/r/D20A8CA9875EN.html>

Date: July 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: D20A8CA9875EN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Down syndrome - Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Down syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Down syndrome Understanding

Down syndrome: Overview

Down syndrome is a condition in which a person has an extra chromosome. Chromosomes are small "packages" of genes in the body. They determine how a baby's body forms and functions as it grows during pregnancy and after birth. Typically, a baby is born with 46 chromosomes. Babies with Down syndrome have an extra copy of one of these chromosomes, chromosome 21. A medical term for having an extra copy of a chromosome is 'trisomy.' Down syndrome is also referred to as Trisomy 21. This extra copy changes how the baby's body and brain develop, which can cause both mental and physical challenges for the baby. Even though people with Down syndrome might act and look similar, each person has different abilities. People with Down syndrome usually have an IQ (a measure of intelligence) in the mildly-to-moderately low

range and are slower to speak than other children.

'Down syndrome - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Down syndrome pipeline landscape is provided which includes the disease overview and Down syndrome treatment guidelines. The assessment part of the report embraces, in depth Down syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Down syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Down syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Down syndrome.

Down syndrome Emerging Drugs Chapters

This segment of the Down syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Down syndrome Emerging Drugs

Aricept: Eisai

Aricept is an acetylcholinesterase inhibitor discovered and developed by Eisai. It increases brain levels of the neurotransmitter acetylcholine by inhibiting its breakdown by acetylcholinesterase. Currently, it is in Phase III stage of development to treat Down syndrome.

ACI-24: AC Immune SA

ACI-24 is an active vaccine stimulating the patient's immune system to produce betasheet conformation-specific antibodies that prevent plaque deposition or enhance clearance of plaques. During preclinical development, the ACI-24 has shown high efficacy in vivo by memory restoration and plaque reduction. The vaccine is also characterized by a very high specificity due to generating a conformation-specific antibody response. The favourable safety profile of ACI-24 is underlined through the absence of local inflammation in relevant models as well as its T-cell independent mechanism shown in preclinical development.

Further product details are provided in the report.....

Down syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Down syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Down syndrome

There are approx. 8+ key companies which are developing the therapies for Down syndrome. The companies which have their Down syndrome drug candidates in the most advanced stage, i.e. phase III include, Eisai.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Down syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Down syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Down syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Down syndrome drugs.

Down syndrome Report Insights

- Down syndrome Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Down syndrome Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Down syndrome drugs?

How many Down syndrome drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Down syndrome?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Down syndrome therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Down syndrome and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Eisai

AC Immune

BioArctic

Aelis Farma

Neuronascent

Annovis Bio

Elixirgen

KinoPharma

Aphios Corporation

Key Products

Aricept

ACI 24

Lecanemab

AEF 0217

NNI 351

R-phenserine

Research programme: ZSCAN4 gene therapy

ABI-02

Contents

Introduction

Executive Summary

Down syndrome: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

Aricept: Eisai

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

ACI 24: AC Immune

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
Comparative Analysis
AEF 0217: Aelis Farma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....

Inactive Products
Comparative Analysis
Down syndrome Key Companies
Down syndrome Key Products
Down syndrome- Unmet Needs
Down syndrome- Market Drivers and Barriers
Down syndrome- Future Perspectives and Conclusion
Down syndrome Analyst Views
Down syndrome Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Down syndrome

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Down syndrome
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Down syndrome - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/D20A8CA9875EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D20A8CA9875EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970